Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

NCT06740916 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Myeloproliferative Neoplasms (MPN)

Interventions

DRUG: 81-mg aspirin once daily
DRUG: 81-mg aspirin twice daily

Sponsor

Siriraj Hospital